<DOC>
	<DOC>NCT00046787</DOC>
	<brief_summary>The purpose of this study is to determine whether OSI-211 (Liposomal Lurtotecan) is an effective and safe treatment for patients with recurrent small cell lung cancer.</brief_summary>
	<brief_title>Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Small Cell</mesh_term>
	<mesh_term>Lurtotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Confirmed recurrent small cell lung cancer. One prior treatment of chemotherapy. At least three weeks since last chemotherapy treatment and recovery from any related side effects. At least three weeks since last chest radiotherapy and at least 10 days since head irradiation and recovery from acute side effects. At least one target tumor less than or equal to 20 mm (or less than or equal to 10 mm on spiral CTscan). If a patient has had previous documented Central Nervous System (CNS) involvement, only controlled disease is acceptable. Superior vena cava syndrome.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>